Enzo Biochem's Clinical Lab Takes Major Step in Becoming National Provider of Predictive Diagnostics

Pennsylvania Grants Lab License to Operate, With Several Others Pending

NEW YORK--(BUSINESS WIRE)-- In the first of several moves to expand the Company's position as a national provider of esoteric and high value diagnostics, Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Enzo Clinical Labs division has been awarded a license for doing business in the Commonwealth of Pennsylvania, the first of several for which it has applied.

"Patient care is moving increasingly to predictive diagnostics utilizing markers and gene based programs, and Enzo Clinical Labs, owing to its highly regarded New York State certification, is increasingly focused on developing into a national leader for the application of esoteric testing and the diagnosis of these specimens," said Kevin Krenitsky, M.D., President of the Clinical Labs Division. "The granting of our license by Pennsylvania is thus a significant step in our ability to solicit business and accept specimens from locations other than the metropolitan New York area, where traditionally most of our business has derived."

The Lab, headquartered in Farmingdale, NY, currently has pending license applications with the states of Maine, Maryland and California.

"In recent years, our Company has invested heavily in the Clinical Lab, expanding our physical plant, adding advanced diagnostic equipment, and installing state of the art accounting systems and communications functionality, to speed accurate and prompt reports to our physician clients," said Barry Weiner, President of Enzo Biochem. "Most notably, we have invested in top level professionals, attracting to the Lab highly regarded pathologists and experienced leaders in the diagnostics field.

"While we continue to perform routine testing, our expanded capabilities will enable our diagnostic laboratory facilities on Long Island to provide what we expect will be an increasing level of higher performance tests sent to us from physicians in all parts of the country," added Mr. Weiner.

Among the unique clinical diagnostic tests in development by Enzo are the ColonSentry(TM) colon cancer risk-stratification assay, multiplex DNA sequencing, alternative amplification/detection methods for pathogens, and cytogenetic tests for cancer using Enzo proprietary probe technology.

About Enzo Biochem

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area. Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics. Enzo Clinical Labs also provides clinical diagnostic services that allow Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics. Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. It has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. In the course of the company's research and development activities, Enzo has developed a substantial portfolio of intellectual property assets, with over 240 issued patents worldwide and over 200 pending patent applications.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

    Source: Enzo Biochem, Inc.